| Autor: |
Jeanne M. Wallace, Margrit Schwarz, Peter Coward, Jonathan Houze, Janet K. Sawyer, Kathryn L. Kelley, Anne Chai, Lawrence L. Rudel |
| Jazyk: |
angličtina |
| Rok vydání: |
2005 |
| Předmět: |
|
| Zdroj: |
Journal of Lipid Research, Vol 46, Iss 5, Pp 1009-1016 (2005) |
| Druh dokumentu: |
article |
| ISSN: |
0022-2275 |
| DOI: |
10.1194/jlr.M500002-JLR200 |
| Popis: |
The objective of this study was to demonstrate the efficacy of a novel peroxisome proliferator-activated receptor (PPAR) agonist and known PPARα and PPARδ agonists to increase HDL-cholesterol (HDL-C) in the St. Kitts vervet, a nonhuman primate model of atherosclerosis. Four groups (n = 6) were studied and each group was assigned one of the following “treatments”: a) vehicle only (vehicle); b) the PPARδ selective agonist GW501516 (GW); c) the PPARα/δ agonist T913659 (T659); and d) the PPARα agonist TriCor® (fenofibrate). No statistically significant changes were seen in body weight, total plasma cholesterol, plasma triglycerides, VLDL-C, LDL-C, or apolipoprotein B (apoB) concentrations. Each of the PPARα and PPARδ agonists investigated in this study increased plasma HDL-C, apoA-I, and apoA-II concentrations and increased HDL particle size in St. Kitts vervets. The maximum percentage increase in HDL-C from baseline for each group was as follows: vehicle, 5%; GW, 43%; T659, 43%; and fenofibrate, 20%. Treatment with GW and T659 resulted in an increase in medium-sized HDL particles, whereas fenofibrate showed increases in large HDL particles.These data provide additional evidence that PPARα and PPARδ agonists (both mixed and selective) have beneficial effects on HDL-C in these experimental primates. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
